The United States Attorney’s Office announced on January 29, 2007, in Boston, Massachusetts that it is intervening in a whistleblower lawsuit filed against Boehringer Ingelheim Roxane, Inc. (”Roxane”) The allegations center around the contention that Roxane reported inflated prices for numerous pharmaceutical products knowing the federal health care programs would establish reimbursement rates based on these fraudulent prices. According to the Government’s complaint, these reported prices were in excess of 1,000 percent of the actual sales prices on several of the drugs it manufactures. It is alleged that damages to federal programs exceeds $500 million.

To read more about pharmaceutical fraud, click here.